Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro.

Wang RR, Yang QH, Luo RH, Peng YM, Dai SX, Zhang XJ, Chen H, Cui XQ, Liu YJ, Huang JF, Chang JB, Zheng YT.

PLoS One. 2014 Aug 21;9(8):e105617. doi: 10.1371/journal.pone.0105617. eCollection 2014.

2.

A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine.

Borroto-Esoda K, Parkin N, Miller MD.

Antivir Chem Chemother. 2007;18(5):297-300.

PMID:
18046962
3.

The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase.

Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH.

J Mol Biol. 2000 Jul 7;300(2):403-18.

PMID:
10873473
4.

Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF.

Antivir Chem Chemother. 2000 Jul;11(4):291-301.

PMID:
10950391
6.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, Kleim JP, Balzarini J, Desmyter J, De Clercq E, Vandamme AM.

AIDS. 2001 Mar 30;15(5):553-61.

PMID:
11316991
7.
8.

Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.

Miller MD, Haddad M, Su C, Gibbs C, McColl DJ, Guyer B.

Antivir Ther. 2012;17(6):993-9. doi: 10.3851/IMP2266. Epub 2012 Jul 26.

PMID:
22837442
9.

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

Margot NA, Waters JM, Miller MD.

Antimicrob Agents Chemother. 2006 Dec;50(12):4087-95. Epub 2006 Sep 18.

10.

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL, Bethell RC.

Antimicrob Agents Chemother. 2006 Feb;50(2):625-31.

11.
12.

Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.

Chong Y, Chu CK.

Antiviral Res. 2004 Jul;63(1):7-13.

PMID:
15196815
13.

Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.

Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW Jr, Bedard J, Rando RF, McCune JM.

Antimicrob Agents Chemother. 2000 Mar;44(3):783-6.

14.
15.

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.

Antivir Chem Chemother. 2003 Jan;14(1):49-59.

PMID:
12790516
16.

The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.

Miller V, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune MP, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA.

AIDS. 1998 May 7;12(7):705-12.

PMID:
9619801
17.

Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.

Barnas D, Koontz D, Bazmi H, Bixby C, Jemsek J, Mellors JW.

Antivir Ther. 2010;15(3):437-41. doi: 10.3851/IMP1539.

18.

Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.

Xu HT, Colby-Germinario SP, Oliveira M, Rajotte D, Bethell R, Wainberg MA.

Antimicrob Agents Chemother. 2014 Aug;58(8):4515-26. doi: 10.1128/AAC.02729-14. Epub 2014 May 27.

19.

Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages.

Aquaro S, Svicher V, Ceccherini-Silberstein F, Cenci A, Marcuccilli F, Giannella S, Marcon L, Caliò R, Balzarini J, Perno CF.

J Antimicrob Chemother. 2005 Jun;55(6):872-8. Epub 2005 Apr 21.

PMID:
15845785
20.

Targeting host nucleotide biosynthesis with resveratrol inhibits emtricitabine-resistant HIV-1.

Heredia A, Davis C, Amin MN, Le NM, Wainberg MA, Oliveira M, Deeks SG, Wang LX, Redfield RR.

AIDS. 2014 Jan 28;28(3):317-23. doi: 10.1097/QAD.0000000000000168.

Supplemental Content

Support Center